The CONFORM Pivotal Trial

Inclusion Criteria

• •1. Male or non-pregnant female aged ≥18 years
• •2. Documented non-valvular AF (paroxysmal, persistent, or permanent)
• •3. High risk of stroke or systemic embolism, defined as CHA2DS2-VASc score of ≥ 3
• •4. Has an appropriate rationale to seek a non-pharmacologic alternative to long-term oral anticoagulation
• •5. Deemed by the site investigator to be suitable for short term oral anticoagulation therapy but deemed less favorable for long-term oral anticoagulation therapy.
• •6. Deemed appropriate for LAA closure by the site investigator and a clinician not a part of the procedural team using a shared decision-making process in accordance with standard of care
• •7. Able to comply with the protocol-specified medication regimen and follow-up evaluations
• •8. The subject (or legally authorized representative, where allowed) has been informed of the nature of the study, agrees to its provisions, and has provided written informed consent approved by the appropriate institutional review board (IRB)/Regional Ethics Board (REB)/Ethics Committee (EC).
• •8. Recent (within 30 days of index procedure) or planned (within 60 days post-procedure) cardiac or major non-cardiac interventional or surgical procedure
• •9. Recent (within 30 days of index procedure) stroke or transient ischemic attack
• •10. Recent (within 30 days of index procedure) myocardial infarction
• •11. Vascular access precluding delivery of implant with catheter-based system
• •12. Severe heart failure (New York Heart Association Class IV)
• •13. Prior cardiac transplant, history of mitral valve replacement or transcatheter mitral valve intervention, or any prosthetic mechanical valve implant
• •14. Renal insufficiency, defined as estimated glomerular filtration rate (eGFR) \<30 mL/min/1.73 m2 (by the Modification of Diet in Renal Disease equation)
• •15. Platelet count \<75,000 cells/mm3 or \>700,000 cells/mm3, or white blood cell count \<3,000 cells/mm3
• •16. Known allergy, hypersensitivity or contraindication to aspirin, heparin, or device materials (e.g., nickel, titanium) that would preclude any P2Y12 inhibitor therapy, or the patient has contrast sensitivity that cannot be adequately pre-medicated
• •17. Actively enrolled or plans to enroll in a concurrent clinical study in which the active treatment arm may confound the results of this trial
• •18. Unable to undergo general anesthesia
• •19. Known other medical illness or known history of substance abuse that may cause non-compliance with the protocol or protocol-specified medication regimen, confound the data interpretation, or is associated with a life expectancy of less than 5 years
• •20. A condition which precludes adequate transesophageal echocardiographic assessment